Navigation Links
Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer

being studied as a single agent and in combination with docetaxel chemotherapy in two Phase 3 clinical trials expected to enroll approximately 1,200 patients with metastatic HRPC. Cell Genesys received Special Protocol Assessments (SPA) from the Food and Drug Administration (FDA) for each of the Phase 3 studies and has also received Fast Track designation for the product. GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a non patient-specific, "off-the-shelf" pharmaceutical product.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently developing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties tha
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
2. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
11. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
Post Your Comments:
(Date:7/22/2014)... July 22, 2014  Decision Resources Group finds that the ... will remain relatively stagnant at a value of ... that percutaneous coronary intervention (PCI) volumes are growing faster in ... such as the United States and ... driven by the increase in penetration of PCI procedures relative ...
(Date:7/22/2014)... WASHINGTON , July 22, 2014 ... "Ensuring Seniors Access to Local Pharmacies Act of ... Medicare Part D would undermine the availability of ... spending by $21 billion over the next 10 ... Company released by the Pharmaceutical Care Management Association ...
(Date:7/22/2014)... July 22, 2014  Decision Resources Group finds ... (MS) patients currently treated with Biogen Idec,s ... experienced flushing and/or gastrointestinal events while on ... currently experiencing these side effects, signifying either ... management of such events. In the end, ...
Breaking Medicine Technology:The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 3
... Pa., Dec. 29, 2010 Endo Pharmaceuticals (Nasdaq: ... and Drug Administration (FDA) has approved FORTESTA Gel for ... known as hypogonadism. Symptoms associated with Low T include ... of energy, mood depression, regression of secondary sexual characteristics ...
... Dr. David Samadi, the Vice Chairman, Department of Urology, ... The Mount Sinai Medical Center in New York City, ... completion of six successful robotic prostate cancer treatment ... three of which were televised live, Samadi demonstrated his ...
Cached Medicine Technology:Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone 2Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone 3Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone 4Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone 5Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone 6Robotic Surgery Expert Dr. David Samadi, MD Determines Live Robotic Prostate Cancer Surgeries During Israel Trip A Success 2Robotic Surgery Expert Dr. David Samadi, MD Determines Live Robotic Prostate Cancer Surgeries During Israel Trip A Success 3
(Date:7/22/2014)... The Beryl Institute announces its fifth annual ... Program. These offerings reinforce the Institute’s commitment to support ... and the need for rigorous research to understand and ... programs are intended to encourage and support research ... on the patient experience before, during and after care ...
(Date:7/22/2014)... Ticket Down is a reliable source for cheap ... Landover, MD. There has never been a better time in ... the success of the American national soccer team at the 2014 ... way that fans of the world’s sport will be able to ... International Champions Cup. The tournament will kick off on July 24 ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... Angeles, CA (PRWEB) July 22, 2014 ... the way in providing resources, educational tools and recognition ... tell the stories of prevention, treatment and recovery. On ... BLACK BOX will spotlight some of these resources with ... Health Services Administration helpline and treatment website at the ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The park ... at the Kendalltown Homeowners Association, Inc., made ... its residential community with the purchase of playground equipment ... is located in beautiful Miami Florida, and is a ... maturity of the surrounding landscape has created a tropical ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... , MONDAY, April 18 (HealthDay News) -- Hospitals are ... not have hemophilia, a rare disorder in which blood does ... patients is potentially risky, according to new research. Stanford ... recombinant factor 7a, grew by 140 times from use in ...
... HealthDay Reporter , MONDAY, April 18 (HealthDay News) -- Gay ... live in communities where they feel they have some support, ... same-sex couples live in the area, new research has found. ... Pediatrics , lesbian, gay and bisexual (LGB) youths who ...
... , MONDAY, April 18 (HealthDay News) -- Most people with ... their ability to smell anything at all -- adjust and learn ... usually appear to place less importance on the sense of smell ... smell. The study included 470 people, half who either lacked ...
... April 18 (HealthDay News) -- Healthy lifestyle changes can ... blood fat associated with heart disease and other health ... Monday. About one-third (31 percent) of adults in ... more than 150 milligrams per deciliter (mg/dL). These ...
... list, can reduce problems with recurring low back pain, reveals ... people suffer with low back pain, and most get better. ... their work, everyday and leisure activities are limited to varying ... is important that the pain be treated at an early ...
... of every 6 kids in the United States, in part ... play a key part in offering elementary-age kids lots of ... they,re in gym. But recent increasing expectations about academic ... cut back on both recess and gym class. The ...
Cached Medicine News:Health News:Off-Label Use of Clotting Drug Soars, Report Finds 2Health News:Support May Help Curb Suicide Among Gay Youths 2Health News:Support May Help Curb Suicide Among Gay Youths 3Health News:Poor Sense of Smell Not a Big Loss for Most People: Study 2Health News:Lifestyle Changes Can Slash Blood Fat Levels, Experts Say 2Health News:Immediate treatment can alleviate future back problems 2Health News:U-M experts: Gym gone but not forgotten? Parents want more physical activity at school for kids 2
... is designed for arthroscopic or open suturing ... It features heavy-gauge suture hooks and the ... hooks allow precise suture placement in otherwise ... System is for use with #2/0 to ...
Suture Cutter, 15 Up Curve...
Portal accessory instrument set. Set also includes a package of 8 mm Guide Wires (.15 cm x 38 cm), and Sterilization Tray....
...
Medicine Products: